Cresanto Global
BSE: CRESANTO · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Cresanto Global's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Cresanto Global Services Limited is an Indian non-banking financial company primarily engaged in investment activities, including the trading of shares and securities. The firm also provides loans and advances to corporate and individual clients while offering financial consultancy services.
Business Model
The company operates a lean business model focused on capital market operations, generating revenue through interest income from lending activities and capital gains from its investment portfolio.
Management Commentary
The company has recently undergone a rebranding process to better align with its evolving corporate identity and strategic focus on financial services.
Growth Outlook
Growth is expected to be driven by the active management of its investment portfolio and the expansion of its financial consultancy operations.
Key Risks
- Market Volatility. As the company relies on trading shares and securities, fluctuations in the capital markets directly impact its profitability.
- Credit Risk. The provision of loans and advances exposes the firm to potential defaults by corporate and individual borrowers.
- Regulatory Risk. Changes in the regulatory framework governing non-banking financial companies in India could necessitate operational adjustments.
- Liquidity Risk. The company's reliance on investment portfolios may lead to liquidity constraints during periods of market stress.
Start your research today
Unlock AI insights, financials, peers and live data on Cresanto Global and 5,000+ companies — free.
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Cresanto GlobalCRESANTO | ₹2 Cr | — | — | — | -580.0% | — | — | — |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Mar 2026
Financials
Cresanto Global
BSE: CRESANTO · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Cresanto Global's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Cresanto Global Services Limited is an Indian non-banking financial company primarily engaged in investment activities, including the trading of shares and securities. The firm also provides loans and advances to corporate and individual clients while offering financial consultancy services.
Business Model
The company operates a lean business model focused on capital market operations, generating revenue through interest income from lending activities and capital gains from its investment portfolio.
Management Commentary
The company has recently undergone a rebranding process to better align with its evolving corporate identity and strategic focus on financial services.
Growth Outlook
Growth is expected to be driven by the active management of its investment portfolio and the expansion of its financial consultancy operations.
Key Risks
- Market Volatility. As the company relies on trading shares and securities, fluctuations in the capital markets directly impact its profitability.
- Credit Risk. The provision of loans and advances exposes the firm to potential defaults by corporate and individual borrowers.
- Regulatory Risk. Changes in the regulatory framework governing non-banking financial companies in India could necessitate operational adjustments.
- Liquidity Risk. The company's reliance on investment portfolios may lead to liquidity constraints during periods of market stress.
Start your research today
Unlock AI insights, financials, peers and live data on Cresanto Global and 5,000+ companies — free.
Peers · Pharmaceuticals
As of Mar 2026